Niquitin Clear (Nicotine)

Nicotine, the active ingredient in Niquitin Clear, is a nicotine replacement therapy presented as a transdermal patch for transdermal use. It is intended to help adult smokers quit by reducing nicotine withdrawal symptoms and supporting cessation efforts.\n\nGNH India supplies Niquitin Clear as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Niquitin Clear is a nicotine replacement product used in the management of tobacco dependence and related withdrawal.\n\n- Smoking cessation: assists adult smokers in quitting by providing a steady nicotine supply.\n- Nicotine withdrawal: alleviates cravings, irritability, and other withdrawal symptoms.\n- Relapse prevention: supports maintenance of abstinence after initial quitting.

Niquitin Clear may cause a range of adverse reactions, most of which are mild and reversible.\n\nCommon Side Effects:\n- Skin irritation at the application site\n- Itching or redness where the patch is placed\n- Sleep disturbance or vivid dreams\n- Nausea or mild gastrointestinal upset\n\nSerious or Rare Side Effects:\n- Allergic reaction such as rash, swelling, or difficulty breathing\n- Severe skin reaction (e.g., bullous dermatitis)\n- Chest pain, rapid heartbeat, or hypertension

When considering Niquitin Clear, certain safety measures should be observed.\n\n- Cardiovascular assessment: use with caution in patients with recent myocardial infarction or unstable angina.\n- Non‑smoker use: not indicated for individuals who do not currently smoke.\n- Concomitant nicotine products: avoid using other nicotine replacement therapies simultaneously to prevent overdose.\n- Child safety: keep patches out of reach of children and pets to avoid accidental exposure.\n- Store at room temperature: keep in the original packaging, protect from moisture and direct heat.

Niquitin Clear can interact with other medicines, requiring attention to avoid adverse outcomes.\n\nMajor Interactions (Avoid):\n- Other nicotine‑containing products: risk of nicotine toxicity.\n- Strong CYP2A6 inhibitors (e.g., methoxsalen): may increase nicotine plasma levels.\n\nModerate Interactions (Monitor Closely):\n- Beta‑blockers: nicotine‑induced tachycardia may be masked.\n- Insulin or oral hypoglycemics: nicotine can affect blood glucose control.\n- Warfarin: nicotine may alter anticoagulant effect, requiring INR monitoring.